CN1602889A - 一种克林霉素磷酸脂粉针剂的制备方法 - Google Patents
一种克林霉素磷酸脂粉针剂的制备方法 Download PDFInfo
- Publication number
- CN1602889A CN1602889A CN 200410057318 CN200410057318A CN1602889A CN 1602889 A CN1602889 A CN 1602889A CN 200410057318 CN200410057318 CN 200410057318 CN 200410057318 A CN200410057318 A CN 200410057318A CN 1602889 A CN1602889 A CN 1602889A
- Authority
- CN
- China
- Prior art keywords
- phosphoric acid
- clindamycin
- filter
- clindamycin phosphate
- acid fat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002347 injection Methods 0.000 title claims description 29
- 239000007924 injection Substances 0.000 title claims description 29
- 238000002360 preparation method Methods 0.000 title claims description 15
- UFUVLHLTWXBHGZ-MGZQPHGTSA-N [(2r,3r,4s,5r,6r)-6-[(1s,2s)-2-chloro-1-[[(2s,4r)-1-methyl-4-propylpyrrolidine-2-carbonyl]amino]propyl]-4,5-dihydroxy-2-methylsulfanyloxan-3-yl] dihydrogen phosphate Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](OP(O)(O)=O)[C@@H](SC)O1 UFUVLHLTWXBHGZ-MGZQPHGTSA-N 0.000 title abstract description 16
- 229960002291 clindamycin phosphate Drugs 0.000 title abstract description 16
- 239000000843 powder Substances 0.000 title abstract description 5
- 239000000243 solution Substances 0.000 claims abstract description 15
- 238000001914 filtration Methods 0.000 claims abstract description 14
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 10
- 238000000034 method Methods 0.000 claims abstract description 9
- 239000006228 supernatant Substances 0.000 claims abstract description 7
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 76
- 229960002227 clindamycin Drugs 0.000 claims description 45
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 claims description 45
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 38
- 239000002537 cosmetic Substances 0.000 claims description 19
- 230000001476 alcoholic effect Effects 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 8
- 238000012856 packing Methods 0.000 claims description 8
- 239000007787 solid Substances 0.000 claims description 8
- 239000004744 fabric Substances 0.000 claims description 6
- 239000005909 Kieselgur Substances 0.000 claims description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 4
- 238000003825 pressing Methods 0.000 claims description 4
- 238000001953 recrystallisation Methods 0.000 claims description 4
- 229910052719 titanium Inorganic materials 0.000 claims description 4
- 239000010936 titanium Substances 0.000 claims description 4
- 206010002198 Anaphylactic reaction Diseases 0.000 abstract description 5
- 206010018910 Haemolysis Diseases 0.000 abstract description 5
- 230000036783 anaphylactic response Effects 0.000 abstract description 5
- 208000003455 anaphylaxis Diseases 0.000 abstract description 5
- 230000008588 hemolysis Effects 0.000 abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 3
- 239000000654 additive Substances 0.000 abstract description 3
- 210000004204 blood vessel Anatomy 0.000 abstract description 3
- 230000000638 stimulation Effects 0.000 abstract description 3
- 239000012535 impurity Substances 0.000 abstract description 2
- 238000010253 intravenous injection Methods 0.000 abstract description 2
- 239000013078 crystal Substances 0.000 abstract 2
- 230000000996 additive effect Effects 0.000 abstract 1
- 238000004042 decolorization Methods 0.000 abstract 1
- 238000001035 drying Methods 0.000 abstract 1
- 239000000945 filler Substances 0.000 abstract 1
- 238000004806 packaging method and process Methods 0.000 abstract 1
- 239000000047 product Substances 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000001990 intravenous administration Methods 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241000700199 Cavia porcellus Species 0.000 description 3
- 230000004520 agglutination Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- 240000007711 Peperomia pellucida Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229960000935 dehydrated alcohol Drugs 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- -1 lactone compound Chemical class 0.000 description 2
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical class CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 206010018873 Haemoconcentration Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 108050008598 Phosphoesterases Proteins 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- POUMFISTNHIPTI-BOMBIWCESA-N hydron;(2s,4r)-n-[(1r,2r)-2-hydroxy-1-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide;chloride Chemical compound Cl.CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 POUMFISTNHIPTI-BOMBIWCESA-N 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- 229960001595 lincomycin hydrochloride Drugs 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000009781 safety test method Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000002132 β-lactam antibiotic Substances 0.000 description 1
- 229940124586 β-lactam antibiotics Drugs 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410057318 CN1274313C (zh) | 2004-08-27 | 2004-08-27 | 一种克林霉素磷酸酯粉针剂的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410057318 CN1274313C (zh) | 2004-08-27 | 2004-08-27 | 一种克林霉素磷酸酯粉针剂的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1602889A true CN1602889A (zh) | 2005-04-06 |
CN1274313C CN1274313C (zh) | 2006-09-13 |
Family
ID=34666231
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200410057318 Active CN1274313C (zh) | 2004-08-27 | 2004-08-27 | 一种克林霉素磷酸酯粉针剂的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1274313C (zh) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101439022B (zh) * | 2008-12-17 | 2010-07-14 | 华北制药集团海翔医药有限责任公司 | 一种克林霉素磷酸酯粉针剂原料药的制备方法 |
CN101829060A (zh) * | 2010-04-30 | 2010-09-15 | 湖北荷普药业有限公司 | 一种注射用克林霉素磷酸酯粉针剂的制备方法 |
CN101928307A (zh) * | 2010-08-24 | 2010-12-29 | 安徽省皖北药业股份有限公司 | 一种克林霉素磷酸酯的结晶方法 |
CN1813785B (zh) * | 2005-12-12 | 2012-09-05 | 王冕 | 一种盐酸克林霉素粉针剂的制备方法 |
CN102731585A (zh) * | 2012-07-23 | 2012-10-17 | 江西省康华医药科技有限公司 | 一种新活性克林霉素磷酸酯化合物及其药物组合物 |
CN101838298B (zh) * | 2009-03-16 | 2013-01-02 | 珠海亿邦制药股份有限公司 | 克林霉素磷酸酯溶剂化物晶体及其制备方法 |
CN102973595A (zh) * | 2012-11-28 | 2013-03-20 | 海南锦瑞制药股份有限公司 | 一种克林霉素磷酸酯的药物组合物 |
CN103142507A (zh) * | 2011-12-07 | 2013-06-12 | 重庆药友制药有限责任公司 | 一种注射用克林霉素磷酸酯制剂及其制备方法 |
CN103275142A (zh) * | 2013-06-05 | 2013-09-04 | 天津大学 | 克林霉素磷酸酯的新晶型α及制备方法 |
CN103275143A (zh) * | 2013-06-05 | 2013-09-04 | 天津大学 | 克林霉素磷酸酯的新晶型β及制备方法 |
CN103288893A (zh) * | 2013-06-05 | 2013-09-11 | 天津大学 | 克林霉素磷酸酯二甲基亚砜溶剂化合物晶体及制备方法 |
CN103288894A (zh) * | 2013-06-05 | 2013-09-11 | 天津大学 | 克林霉素磷酸酯甲醇-水溶剂化合物晶体及制备方法 |
CN108030769A (zh) * | 2017-12-11 | 2018-05-15 | 山西普德药业有限公司 | 一种注射用克林霉素磷酸酯的制备方法 |
CN111000803A (zh) * | 2019-12-03 | 2020-04-14 | 珠海亿邦制药有限责任公司 | 一种注射用克林霉素磷酸酯药物组合物的制备工艺 |
CN112206212A (zh) * | 2020-10-16 | 2021-01-12 | 海南锦瑞制药有限公司 | 一种注射用克林霉素磷酸酯的制备方法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102690300B (zh) * | 2009-03-16 | 2014-07-30 | 珠海亿邦制药股份有限公司 | 克林霉素磷酸酯溶剂化物晶体及其制备方法 |
-
2004
- 2004-08-27 CN CN 200410057318 patent/CN1274313C/zh active Active
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1813785B (zh) * | 2005-12-12 | 2012-09-05 | 王冕 | 一种盐酸克林霉素粉针剂的制备方法 |
CN101439022B (zh) * | 2008-12-17 | 2010-07-14 | 华北制药集团海翔医药有限责任公司 | 一种克林霉素磷酸酯粉针剂原料药的制备方法 |
CN101838298B (zh) * | 2009-03-16 | 2013-01-02 | 珠海亿邦制药股份有限公司 | 克林霉素磷酸酯溶剂化物晶体及其制备方法 |
CN101829060A (zh) * | 2010-04-30 | 2010-09-15 | 湖北荷普药业有限公司 | 一种注射用克林霉素磷酸酯粉针剂的制备方法 |
CN101829060B (zh) * | 2010-04-30 | 2011-12-28 | 湖北荷普药业有限公司 | 一种注射用克林霉素磷酸酯粉针剂的制备方法 |
CN101928307A (zh) * | 2010-08-24 | 2010-12-29 | 安徽省皖北药业股份有限公司 | 一种克林霉素磷酸酯的结晶方法 |
CN101928307B (zh) * | 2010-08-24 | 2013-07-10 | 安徽省皖北药业股份有限公司 | 一种克林霉素磷酸酯的结晶方法 |
CN103142507A (zh) * | 2011-12-07 | 2013-06-12 | 重庆药友制药有限责任公司 | 一种注射用克林霉素磷酸酯制剂及其制备方法 |
CN102731585A (zh) * | 2012-07-23 | 2012-10-17 | 江西省康华医药科技有限公司 | 一种新活性克林霉素磷酸酯化合物及其药物组合物 |
CN102731585B (zh) * | 2012-07-23 | 2013-09-11 | 江西省康华医药科技有限公司 | 一种活性克林霉素磷酸酯化合物及其药物组合物 |
CN102973595A (zh) * | 2012-11-28 | 2013-03-20 | 海南锦瑞制药股份有限公司 | 一种克林霉素磷酸酯的药物组合物 |
CN102973595B (zh) * | 2012-11-28 | 2013-12-11 | 海南锦瑞制药股份有限公司 | 一种克林霉素磷酸酯的药物组合物 |
CN103288893A (zh) * | 2013-06-05 | 2013-09-11 | 天津大学 | 克林霉素磷酸酯二甲基亚砜溶剂化合物晶体及制备方法 |
CN103288894A (zh) * | 2013-06-05 | 2013-09-11 | 天津大学 | 克林霉素磷酸酯甲醇-水溶剂化合物晶体及制备方法 |
CN103275143A (zh) * | 2013-06-05 | 2013-09-04 | 天津大学 | 克林霉素磷酸酯的新晶型β及制备方法 |
CN103275142A (zh) * | 2013-06-05 | 2013-09-04 | 天津大学 | 克林霉素磷酸酯的新晶型α及制备方法 |
CN103288893B (zh) * | 2013-06-05 | 2015-08-19 | 天津大学 | 克林霉素磷酸酯二甲基亚砜溶剂化合物晶体及制备方法 |
CN103288894B (zh) * | 2013-06-05 | 2015-08-19 | 天津大学 | 克林霉素磷酸酯甲醇-水溶剂化合物晶体及制备方法 |
CN103275143B (zh) * | 2013-06-05 | 2016-06-08 | 天津大学 | 克林霉素磷酸酯的新晶型β及制备方法 |
CN103275142B (zh) * | 2013-06-05 | 2016-06-08 | 天津大学 | 克林霉素磷酸酯的新晶型α及制备方法 |
CN108030769A (zh) * | 2017-12-11 | 2018-05-15 | 山西普德药业有限公司 | 一种注射用克林霉素磷酸酯的制备方法 |
CN111000803A (zh) * | 2019-12-03 | 2020-04-14 | 珠海亿邦制药有限责任公司 | 一种注射用克林霉素磷酸酯药物组合物的制备工艺 |
CN112206212A (zh) * | 2020-10-16 | 2021-01-12 | 海南锦瑞制药有限公司 | 一种注射用克林霉素磷酸酯的制备方法 |
CN112206212B (zh) * | 2020-10-16 | 2023-04-28 | 海南锦瑞制药有限公司 | 一种注射用克林霉素磷酸酯的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN1274313C (zh) | 2006-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1274313C (zh) | 一种克林霉素磷酸酯粉针剂的制备方法 | |
JP4709203B2 (ja) | アルギンオリゴ糖及びその誘導体、並びにそれらの調製と用途 | |
KR102539060B1 (ko) | 만누론 이산의 조성물 | |
DE2634900C2 (de) | 3-Trihydroxygermylpropionsäure, ihre Salze und Verfahren zu deren Herstellung | |
CN100418535C (zh) | 一种七叶皂苷及其制备方法 | |
CN100428940C (zh) | 七叶皂苷的药物组合物及其制备方法和其制药用途 | |
DE2938041A1 (de) | Verfahren zur herstellung von retinoylhydroxysaeurederivaten und arzneimittel, das diese verbindungen enthaelt | |
CN101829060B (zh) | 一种注射用克林霉素磷酸酯粉针剂的制备方法 | |
EP2069334B1 (de) | Aspalathin-ähnliches dihydrochalcon, extrakte aus unfermentiertem rotbusch und verfahren zur herstellung | |
CN102512379B (zh) | 一种新型棘白菌素类抗真菌药物组合物及其制备方法 | |
CN104856946B (zh) | 一种地塞米松磷酸钠注射液及其制备工艺 | |
CN110575464A (zh) | 一种含大麻提取物的消炎喷雾剂及其制备方法 | |
KR101652429B1 (ko) | 봉독 비누의 제조방법 및 상기 방법에 의해 제조된 봉독 비누 | |
CN103120642A (zh) | 一种用于皮肤疾患的凝胶及其制备方法 | |
DE4303823C2 (de) | Verwendung eines Extraktes aus Blüten von Salvia officinalis bei der Bekämpfung von Durchblutungsstörungen | |
CH641678A5 (de) | Entzuendungshemmendes und zur behandlung der benignen prostatahypertrophie geeignetes arzneimittel. | |
CN104610153B (zh) | 奥扎格雷葡甲胺盐及其组合物、制备方法和用途 | |
CN102247490A (zh) | 一种强效皮伤炎乳膏及其制作方法 | |
CN100496461C (zh) | 银杏总黄酮的精制方法及制备银杏达莫注射液的方法 | |
CN112851616B (zh) | 一种圣草酚的半合成方法 | |
CH666273A5 (de) | Verfahren zur herstellung einer neuen haemin-komplexverbindung und diese als wirksubstanz enthaltende pharmazeutische zubereitungen. | |
CN1099871C (zh) | 双甘注射液及其制备方法 | |
DE102007014947B4 (de) | Stabilisierte wässrige Lösungen von Ergolinverbindungen | |
CN1159038C (zh) | 一种治疗烧烫伤的霜剂 | |
Koller | Side-effects and contra-indications of anticoagulants |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: ZHUHAI YIBANG PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: BEIJING GUO REN TANG MEDICAL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. Effective date: 20070518 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20070518 Address after: 519041 Guangdong city of Zhuhai province Jinwan District Road No. 9 East Coast Patentee after: Zhuhai Yibang Pharmaceutical Co., Ltd. Address before: 100027, room 18, 1-1608 Xin Tong Street, Beijing, Dongcheng District Patentee before: Beijing Guorentang Medical Science Developing Co., Ltd. |
|
C56 | Change in the name or address of the patentee |
Owner name: ZHUHAI EBANG PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME: ZHUHAI YIBANG PHARMACEUTICAL CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: 519041 Guangdong city of Zhuhai province Jinwan District Road No. 9 East Coast Patentee after: Zhuhai Ebang Pharmaceutical Co., Ltd. Address before: 519041 Guangdong city of Zhuhai province Jinwan District Road No. 9 East Coast Patentee before: Zhuhai Yibang Pharmaceutical Co., Ltd. |
|
CP01 | Change in the name or title of a patent holder |
Address after: 519041 Guangdong city of Zhuhai province Jinwan District Road No. 9 East Coast Patentee after: Zhuhai Yibang Pharmaceutical Co., Ltd Address before: 519041 Guangdong city of Zhuhai province Jinwan District Road No. 9 East Coast Patentee before: ZHUHAI EBANG PHARMACEUTICAL Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 519041 Guangdong city of Zhuhai province Jinwan District Road No. 9 East Coast Patentee after: Zhuhai Yibang Pharmaceutical Co.,Ltd. Address before: 519041 Guangdong city of Zhuhai province Jinwan District Road No. 9 East Coast Patentee before: ZHUHAI EBANG PHARMACEUTICAL Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder |